-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Benzinga·02/26/2026 11:24:54
Listen to the news
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.